收费全文 | 4024855篇 |
免费 | 285510篇 |
国内免费 | 9089篇 |
耳鼻咽喉 | 55958篇 |
儿科学 | 131878篇 |
妇产科学 | 110697篇 |
基础医学 | 574075篇 |
口腔科学 | 112499篇 |
临床医学 | 370645篇 |
内科学 | 776714篇 |
皮肤病学 | 93110篇 |
神经病学 | 326074篇 |
特种医学 | 152232篇 |
外国民族医学 | 1141篇 |
外科学 | 601318篇 |
综合类 | 83729篇 |
现状与发展 | 15篇 |
一般理论 | 1605篇 |
预防医学 | 314970篇 |
眼科学 | 93791篇 |
药学 | 296494篇 |
16篇 | |
中国医学 | 7875篇 |
肿瘤学 | 214618篇 |
2021年 | 31742篇 |
2019年 | 32549篇 |
2018年 | 44960篇 |
2017年 | 34088篇 |
2016年 | 39162篇 |
2015年 | 44011篇 |
2014年 | 61478篇 |
2013年 | 93049篇 |
2012年 | 125222篇 |
2011年 | 133019篇 |
2010年 | 79984篇 |
2009年 | 76034篇 |
2008年 | 124375篇 |
2007年 | 132177篇 |
2006年 | 134071篇 |
2005年 | 129400篇 |
2004年 | 124490篇 |
2003年 | 119968篇 |
2002年 | 116018篇 |
2001年 | 183149篇 |
2000年 | 187996篇 |
1999年 | 158954篇 |
1998年 | 47208篇 |
1997年 | 41496篇 |
1996年 | 41642篇 |
1995年 | 40030篇 |
1994年 | 36762篇 |
1993年 | 34584篇 |
1992年 | 124643篇 |
1991年 | 120819篇 |
1990年 | 117513篇 |
1989年 | 113898篇 |
1988年 | 104824篇 |
1987年 | 102730篇 |
1986年 | 96735篇 |
1985年 | 92698篇 |
1984年 | 69307篇 |
1983年 | 59004篇 |
1982年 | 35185篇 |
1979年 | 62896篇 |
1978年 | 44722篇 |
1977年 | 37769篇 |
1976年 | 35547篇 |
1975年 | 37973篇 |
1974年 | 45285篇 |
1973年 | 43145篇 |
1972年 | 40607篇 |
1971年 | 38141篇 |
1970年 | 35119篇 |
1969年 | 33802篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Background
Herbal medicine has been widely utilized by pregnant women despite the limited available evidence regarding the safety and efficacy of that practice. The current available studies, from different countries, estimated that the use of herbal medicine during pregnancy range from 7% up to 96%. The aim of this study is to determine the prevalence, attitude, source of information, and reasoning behind the use of herbal medicine among pregnant women in Saudia Arabia.Methods
A cross-sectional study conducted using a convenience sample including pregnant women who visited the obstetric clinics at King Abdulaziz Medical City in Riyadh, Saudi Arabia. A survey was administered in order to evaluate the prevalence and perception toward herbal medicine use among pregnant women in Saudi Arabia.Results
A total of 297 pregnant women completed the survey. The results showed that 56% of the respondents have used some type of herbal medicine during their pregnancy. Olive oil was utilized in 26% of the respondents followed by cumin 20% and garlic 15%. In addition, 37% of the respondents used herbal medicine by their own initiative, while 33% and 12% used herbal medicine based on recommendations from their families and friends, respectively. Furthermore, 19% of the respondents reported a positive attitude toward herbal medicine use during pregnancy. In addition, the percentage of women with positive attitude was marginally higher among respondents with lower educational level.Conclusion
The prevalence of using herbal medicine is considerably high among pregnant women in Saudi Arabia. Unfortunately, the majority of the users relied on informal sources to use herbal medicine during pregnancy. 相似文献Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献